CytomX Therapeutics CTMX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total External Costs by Product | ||||||
| Cx801Ifnalpha2B | $344K+7.8% | $319K-13.6% | $369K-18.4% | $452K-7.4% | $488K+9.7% | |
| Cx904Egfrxcd3 | $241K— | —— | $150K+127% | -$550K-150% | $1.11M-32.3% | |
| Other Wholly Owned And Partnered Programs | $143K-74.7% | $565K+22.3% | $462K-7.2% | $498K+25.4% | $397K-73.2% | |
| Varseta-M Ep CAM | $7.81M— | —— | —— | —— | $4.27M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does CytomX Therapeutics break its business down?
- CytomX Therapeutics (CTMX) reports total external costs by product across 5 parts — Cx801Ifnalpha2B, Cx904Egfrxcd3, Other Wholly Owned And Partnered Programs, Varseta-M Ep CAM and Varseta-M. Each is extracted from the segment footnotes and tracked over time.
- Where does CytomX Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in CytomX Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
